[Poster] A prospective observational study on breast cancer in Lyon and Dijon: description of the "breast cohort" of the IMODI project

July 12, 2019

Oumaïra Rahmouni (1), Basile Frilley (1), Angélina Dion (1), Florence Gillaizeau (1), Amandine Charreton (2), Patricia Lapierre (3), Cindy Pensec (1), Manuel Desmars (1), Pierre-François Busson (1), Séverine Tabone-Eglinger (2), Isabelle Treilleux (2), Olivier Tredan (2), Françoise Le Vacon (1), Sidonie N Lavergne (1)


(1) Biofortis Mérieux NutriSciences (Saint-Herblain, France), (2) Centre Léon-Bérard (Lyon, France), (3) Centre Georges François Leclerc (Dijon, France)


This poster focuses on the description of a cohort of patients with breast cancer at the time of their recruitment into the IMODI project. The poster was presented at Cancéropôle Grand Ouest on July 1st & 2nd 2019 (Tours, France).


Breast cancer (BC) is the most common cancer among women, in the world and in France (annual incidences of 2,1 million and 58,968 new cases in 2017). IMODI (Innovative MODels Initiative) is a French public-private consortium that aims to accelerate therapeutic innovation, to develop new cancer models, and to study the fecal microbiota associated with cancer.


The main objective here was to describe the cohort of women with BC at the time of their recruitment, according to demographic, epidemiological, clinical, and histopathological criteria. For the BC cohort, 158 patients were recruited by the 2 referral centers, Centre Léon-Bérard (Lyon, France) and Centre Georges François Leclerc (Dijon, France). Of these women, 139 had a localized BC and 19 a metastastic one that were further categorized into primodiagnosis, relapses, and “continuing” cancers (i.e. in follow-up after a diagnosis several years prior to the study).


The conclusions of this study were as follow:

  • Epidemiological, lifestyle and clinical parameters varied between patients with localized vs metastatic BC, and are not directly related to the cancer progression;

  • A low statistical power was noticed due to a relatively small number of patients and their distribution into multiple subgroups.


A confrontation of the patient’s clinical data with diet information and microbiota taxonomic profiles is on-going for patients with a primodiagnosis of localized BC (the largest subgroup in this cohort).


To learn more about these results, or to ask for a copy of this poster, you may contact us on: biofortis-contact@mxns.com




Share on Facebook
Share on Twitter
Share on LinkedIn
Share on Google+
Like this
Please reload


Please reload



  • LinkedIn Biofortis Mérieux NutriSc.
  • Twitter Biofortis Mérieux NutriSc.
  • YouTube Biofortis Mérieux NutriSc.


© 2017 Biofortis Mérieux NutriSciences


As part of Mérieux NutriSciences, Biofortis supports the food and health industries by conducting research projects with a unique nutrition and analytical service. A one-stop shop CRO offering innovative services including clinical assessments, microbiota-related research, sensory evaluation and consumer studies.


  • LinkedIn Biofortis Mérieux NutriSc.
  • Twitter Biofortis Mérieux NutriSc.
  • YouTube Biofortis Mérieux NutriSc.

3 Route de la Chatterie

44800 Saint-Herblain


Tel: +33 2 40 20 57 99